<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427178</url>
  </required_header>
  <id_info>
    <org_study_id>AAAI1718</org_study_id>
    <secondary_id>U54NS078059</secondary_id>
    <nct_id>NCT02427178</nct_id>
    <nct_alias>NCT02363881</nct_alias>
  </id_info>
  <brief_title>MNGIE Allogeneic Hematopoietic Stem Cell Transplant Safety Study</brief_title>
  <acronym>MASS</acronym>
  <official_title>MNGIE (Mitochondrial Neurogastrointestinal Encephalomyopathy) AHSCT (Allogeneic Hematopoietic Stem Cell Transplant) Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michio Hirano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if a stem cell transplant is safe for patients with
      a very rare disease. The stem cell transplant is called AHSCT (for &quot;allogeneic hematopoetic
      stem cell transplantation&quot;). The rare disease is called MNGIE (for &quot;Mitochondrial
      NeuroGastroIntestinal Encephalomyopathy&quot;). Patients with MNGIE will be transplanted with stem
      cells from an individual who is human leukocyte antigen (HLA) 10/10 matched. The purpose of
      the transplant is the production of thymidine phosphorylase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have been identified as having MNGIE by genetic testing and/or reduced thymidine
      phosphorylase levels will be considered for this study. The study team physician will
      evaluate the condition of the patient and determine if they are eligible. An HLA matched
      donor is necessary for transplantation. If a suitable donor is found the transplant process
      can proceed. The patient receives immunosuppressive therapy ( 1 week in the hospital) with
      subsequent IV transfer of stem cells from the donor. The patient remains in the hospital for
      approximately 1 month to monitor the transplant. The patient is required to attend research
      visits at days 0, 100, 6m, 18m and 24 m.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>neutrophil count (cells/L)</measure>
    <time_frame>42 days</time_frame>
    <description>engraftment success</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patient survival days</measure>
    <time_frame>100 days</time_frame>
    <description>is the patient al</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chimerism percentage</measure>
    <time_frame>100 days</time_frame>
    <description>percent of donor cell chimerism at 100 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>micromole/l dUrd</measure>
    <time_frame>100 days</time_frame>
    <description>level of deoxyuridine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>micromole Thd</measure>
    <time_frame>100 days</time_frame>
    <description>level of thymidine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hematopoietic allogeneic stem cells will be transplanted:
HLA testing will be performed on potential stem cell donors. HLA 10/10 matched donors are eligible, however there are additional criteria that will be applied to determine an acceptable donor. Patients will receive 2 X10 6 CD34 cells/kg weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hematopoietic Allogeneic Stem Cells</intervention_name>
    <description>HLA 10/10 matched allogeneic bone marrow cells will be infused into recipient (patient).</description>
    <arm_group_label>Open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Homozygous or compound heterozygous mutations in the TYMP gene

          -  Plasma thymidine level &gt;3micromole/L

          -  Plasma deoxyuridine &gt;7.5 micromole/L

          -  5 to 55 years of age

          -  Appropriate stem cell donor (HLA 10/10 matched)

          -  Karnofsky performance of at least 55

        Exclusion Criteria:

          -  Severe cognitive impairment

          -  Severe psychiatric illness

          -  Moderate to severe lung disease

          -  Prior episode of peritonitis due to perforated diverticula

          -  Prior episode of intestinal pseudo-obstruction

          -  Moderate to severe hepatopathy

          -  Moderate to severe diabetes Mellitus

          -  Moderate to severe cardiomyopathy

          -  Moderate to severe nephropathy

          -  Pregnancy or planning to become pregnant during study

          -  Hypersensitivity to E.coli derived products

          -  HIV disease

          -  Positive to anti-donor HLA DP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michio Hirano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kris Engelstad, MS CGC</last_name>
    <phone>1-212-305-6834</phone>
    <email>ke4@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michio Hirano, MD</last_name>
      <phone>212-305-1048</phone>
      <email>mh29@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kris Engelstad, MS CGC</last_name>
      <phone>1-212-305-6834</phone>
      <email>ke4@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Johnston Grier, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Halter J, Schüpbach W, Casali C, Elhasid R, Fay K, Hammans S, Illa I, Kappeler L, Krähenbühl S, Lehmann T, Mandel H, Marti R, Mattle H, Orchard K, Savage D, Sue CM, Valcarcel D, Gratwohl A, Hirano M. Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone Marrow Transplant. 2011 Mar;46(3):330-337. doi: 10.1038/bmt.2010.100. Epub 2010 May 3.</citation>
    <PMID>20436523</PMID>
  </reference>
  <reference>
    <citation>Martí R, López LC, Hirano M. Assessment of thymidine phosphorylase function: measurement of plasma thymidine (and deoxyuridine) and thymidine phosphorylase activity. Methods Mol Biol. 2012;837:121-33. doi: 10.1007/978-1-61779-504-6_8.</citation>
    <PMID>22215544</PMID>
  </reference>
  <reference>
    <citation>Hirano M, Nishino I, Nishigaki Y, Martí R. Thymidine phosphorylase gene mutations cause mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Intern Med. 2006;45(19):1103. Epub 2006 Nov 1.</citation>
    <PMID>17077575</PMID>
  </reference>
  <reference>
    <citation>Valentino ML, Martí R, Tadesse S, López LC, Manes JL, Lyzak J, Hahn A, Carelli V, Hirano M. Thymidine and deoxyuridine accumulate in tissues of patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). FEBS Lett. 2007 Jul 24;581(18):3410-4. Epub 2007 Jun 27.</citation>
    <PMID>17612528</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>April 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2015</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Michio Hirano</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Allogeneic Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>MNGIE</keyword>
  <keyword>Stem Cell transplant</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>When applicable, we will submit a manuscript describing the results</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

